Integra Buys IsoTis, Gains Accell Demineralized Bone Matrix In $51 Mil. Deal
This article was originally published in The Gray Sheet
Executive Summary
Closure of Integra LifeSciences' acquisition of orthobiologics firm IsoTis is conditioned upon 510(k) clearance for IsoTis' Accell line of demineralized bone matrix products, Integra says